David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $3.31, for a total value of $16,881.00. Following the completion of the transaction, the chief executive officer directly owned 44,579 shares in the company, valued at approximately $147,556.49. This represents a 10.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Whitehawk Therapeutics Stock Down 0.5%

Whitehawk Therapeutics stock opened at $4.01 on Thursday. The stock has a market cap of $188.99 million, a price-to-earnings ratio of 28.64 and a beta of 0.51. Whitehawk Therapeutics, Inc. has a 12 month low of $1.39 and a 12 month high of $4.48. The business has a 50 day moving average price of $2.96 and a two-hundred day moving average price of $2.45.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter.

Analyst Ratings Changes

A number of research firms have issued reports on WHWK. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Monday, December 29th. JonesTrading started coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Whitehawk Therapeutics has an average rating of “Hold” and an average target price of $6.50.

Institutional Investors Weigh In On Whitehawk Therapeutics

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. bought a new position in Whitehawk Therapeutics during the 3rd quarter worth $2,552,000. Peapod Lane Capital LLC acquired a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $577,000. Dimensional Fund Advisors LP bought a new stake in Whitehawk Therapeutics during the 3rd quarter worth $84,000. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics during the third quarter worth about $5,414,000. Finally, Suvretta Capital Management LLC bought a new stake in Whitehawk Therapeutics during the 3rd quarter worth approximately $7,030,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.